格隆汇9月18日丨威高股份(01066.HK)公告，9月18日耗资316.8万港元回购54万股。 ...

智通财经APP讯，威高股份(01066)发布公告，于2025年9月18日该公司斥资316.82万港元回购54万股， 回购价格为每股5.85-5.90港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： 表格類別： 股票 狀態： 新提交 公司名稱： 山東威高集團醫用高分子製品股份有限公司 呈交日期： 2025年9月18日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | ...

Investment Rating - The report maintains a rating of "Accumulate" for the company [6][10]. Core Views - The company's performance in the first half of 2025 shows stability, with revenue from pharmaceuticals and orthopedics leading the growth. The company continues to prioritize high dividend payouts, reflecting its commitment to shareholder returns [2][10]. Financial Summary - Total revenue for 2023 was 13,243.76 million RMB, with a projected increase to 13,889.42 million RMB in 2025, representing a growth of 6.1%. The net profit for 2023 was 2,001.91 million RMB, with a slight decrease expected to 2,033.02 million RMB in 2025, a decline of 1.6% [4][10]. - The company’s cash dividend ratio increased from 30% prior to 2023 to 40% in 2023, with a further increase to 50% expected by the end of 2024. The mid-year dividend for 2025 is also planned to be maintained at 50% [10]. Revenue Breakdown - The general medical device segment generated revenue of 33.0 billion RMB in the first half of 2025, remaining stable year-on-year. The pharmaceutical packaging segment also maintained revenue at 11.7 billion RMB, with significant growth in automatic injection pens, which saw a sales increase of approximately 200% [10]. - The orthopedics segment reported revenue of 7.3 billion RMB, a slight decrease of 1.6%, but with a substantial increase in segment profit by 74%. The interventional segment's revenue was 9.9 billion RMB, down by 2%, while the blood technology segment grew by 8.1% to 4.5 billion RMB [10]. Earnings Forecast - The report adjusts the earnings per share (EPS) forecast for 2025-2027 to 0.44, 0.50, and 0.56 RMB respectively, down from previous estimates of 0.51, 0.57, and 0.63 RMB [10]. - The target price for 2026 is set at 8.00 RMB, equivalent to 8.76 HKD, based on a target price-to-earnings (PE) ratio of 16X [10]. Market Data - The current stock price is 5.90 HKD, with a market capitalization of 26,967 million HKD and a 52-week price range of 4.15 to 7.22 HKD [7][10].

Core Viewpoint - Cathay Securities maintains an "Accumulate" rating for Weigao Group (01066), adjusting the EPS forecast for 2025-2027 to 0.44/0.50/0.56 yuan from the previous 0.51/0.57/0.63 yuan, with a target price of 8.00 yuan (equivalent to 8.76 HKD) based on a target PE of 16X for 2026 [1] Group 1: Financial Performance - In H1 2025, the company achieved sales revenue of 6.64 billion yuan, remaining flat year-on-year; adjusted net profit attributable to shareholders was 1.02 billion yuan, a decrease of 6.1% year-on-year, primarily due to price reductions of certain products and increased marketing expenses for new products [2] Group 2: Revenue Segmentation - The general medical device segment generated revenue of 3.30 billion yuan in H1 2025, remaining stable year-on-year, with key products like infusion sets and syringes maintaining stable prices and slight volume growth [3] - The pharmaceutical packaging segment reported revenue of 1.17 billion yuan, also flat year-on-year, with stable domestic sales prices for pre-filled syringes and significant volume growth of approximately 200% for automatic injection pens in the Chinese market [3] - The orthopedic segment's revenue was 730 million yuan, a slight decline of 1.6% year-on-year, but segment profit increased by 74% year-on-year, with spinal products showing double-digit growth [3] - The interventional segment's revenue was 990 million yuan, down 2% year-on-year, while the blood technology segment saw revenue of 450 million yuan, an increase of 8.1% year-on-year, driven by good overseas recovery of the Radiosonde irradiator [3] Group 3: Shareholder Returns - The company has maintained a cash dividend ratio of 30% prior to 2023, increasing to 40% for the full year of 2023, with plans to further raise the dividend ratio to 50% by the end of 2024; the mid-year dividend for 2025 is also planned to remain at 50%, reflecting a strong commitment to shareholder returns [4]

Core Viewpoint - Cathay Securities maintains a "Buy" rating for Weigao Group (01066), adjusting the EPS forecast for 2025-2027 to 0.44/0.50/0.56 yuan from the previous 0.51/0.57/0.63 yuan, with a target price of 8.00 yuan (equivalent to 8.76 HKD) based on a target PE of 16X for 2026 [1] Group 1: Financial Performance - In H1 2025, the company achieved a sales revenue of 6.64 billion yuan, remaining flat year-on-year; adjusted net profit attributable to shareholders was 1.02 billion yuan, a decrease of 6.1% year-on-year, primarily due to price reductions on some products and increased marketing expenses for new products [2] Group 2: Business Segments Performance - The general medical device segment generated revenue of 3.30 billion yuan in H1 2025, remaining stable year-on-year, with key products like infusion sets and syringes maintaining stable prices and slight volume growth [3] - The pharmaceutical packaging segment reported revenue of 1.17 billion yuan, also flat year-on-year, with stable domestic sales prices for pre-filled syringes and significant volume growth of approximately 200% for automatic injection pens [3] - The orthopedic segment's revenue was 730 million yuan, a slight decline of 1.6% year-on-year, but segment profit increased by 74% year-on-year, with double-digit growth in spinal products [3] - The interventional segment's revenue was 990 million yuan, down 2% year-on-year, while the blood technology segment saw revenue of 450 million yuan, an increase of 8.1% year-on-year, with good recovery in overseas sales of the Radiosurgery device [3] Group 3: Shareholder Returns - The company has maintained a cash dividend ratio of 30% prior to 2023, increasing to 40% for the full year of 2023, and plans to further raise the dividend ratio to 50% by the end of 2024, with a proposed 50% dividend ratio for the mid-2025 period, highlighting a strong commitment to shareholder returns [4]

Summary of Key Points Core Viewpoint - On September 17, 28 Hong Kong-listed companies conducted share buybacks, totaling 16.7684 million shares and an aggregate amount of HKD 649 million [1][2]. Group 1: Share Buyback Details - Tencent Holdings repurchased 839,000 shares for HKD 551 million, with a highest price of HKD 663.50 and a lowest price of HKD 645.50, bringing its total buyback amount for the year to HKD 52.707 billion [1][2]. - Hang Seng Bank repurchased 200,000 shares for HKD 23.8014 million, with a highest price of HKD 119.30 and a lowest price of HKD 118.40, totaling HKD 793 million in buybacks for the year [1][2]. - Pacific Shipping repurchased 6 million shares for HKD 14.9526 million, with a highest price of HKD 2.52 and a lowest price of HKD 2.45, accumulating HKD 203 million in buybacks for the year [1][2]. Group 2: Ranking of Buybacks - The highest buyback amount on September 17 was from Tencent Holdings at HKD 551 million, followed by Hang Seng Bank at HKD 23.8014 million [1][2]. - In terms of share quantity, Pacific Shipping led with 6 million shares repurchased, followed by Linklogis Technology and Weigao Group with 2.3 million and 1.9548 million shares, respectively [1][2]. Group 3: Additional Buyback Information - Other notable companies involved in buybacks include Weigao Group, MGM China, and Jitu Express, with respective buyback amounts of HKD 11.4255 million, HKD 7.873 million, and HKD 7.8348 million [2][3]. - The buyback activity reflects a strategic move by these companies to enhance shareholder value amid market conditions [1][2].

Summary of Key Points Core Viewpoint - Multiple companies, including Tencent Holdings and Hang Seng Bank, conducted share buybacks on September 17, 2025, with Tencent leading in both the number of shares repurchased and the total amount spent. Group 1: Company Buyback Details - Tencent Holdings (00700) repurchased 839,000 shares for a total of 551 million, with a year-to-date total of 58.158 million shares, representing 0.633% of its total share capital [1][2] - Hang Seng Bank (00011) repurchased 200,000 shares for 23.8014 million, with a year-to-date total of 6.93 million shares, representing 0.368% of its total share capital [2] - Pacific Shipping (02343) repurchased 6 million shares for 14.9526 million, with a year-to-date total of 41.006 million shares, representing 0.798% of its total share capital [2] - Weigao Group (01066) repurchased 1.9548 million shares for 11.4255 million, with a year-to-date total of 14.2136 million shares, representing 3.148% of its total share capital [2] - MGM China (02282) repurchased 502,000 shares for 7.873 million, with a year-to-date total of 2.23295 million shares, representing 0.587% of its total share capital [2] Group 2: Other Notable Buybacks - Jitu Express-W (01519) repurchased 870,000 shares for 7.8348 million, with a year-to-date total of 870,000 shares, representing 0.010% of its total share capital [2] - Linkage Technology-W (09959) repurchased 2.3 million shares for 7.4586 million, with a year-to-date total of 19.9075 million shares, representing 0.932% of its total share capital [2] - Mengniu Dairy (02319) repurchased 200,000 shares for 3.074 million, with a year-to-date total of 10.816 million shares, representing 0.276% of its total share capital [2] - China Hongqiao (01378) repurchased 112,500 shares for 2.822 million, with a year-to-date total of 150 million shares, representing 1.610% of its total share capital [2] - Coolpad Group (02369) repurchased 1.348 million shares for 1.8057 million, with a year-to-date total of 23.095 million shares, representing 5.639% of its total share capital [2]

| 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.09.17 | 195.48 | 5.900 | 5.820 | 1142.55 | | 2025.09.16 | 53.00 | 5.940 | 5.820 | 312.22 | | 2025.09.15 | 95.60 | 5.850 | 5.790 | 557.62 | | 2025.09.12 | 31.96 | 5.900 | 5.770 | 187.85 | | 2025.09.11 | 42.92 | 5.690 | 5.570 | 242.48 | | 2025.09.10 | 72.00 | 5.720 | 5.660 | 408.78 | | 2025.09.09 | 114.00 | 5.750 | 5.700 | 652.12 | | 2025.09.08 | 47.28 | 5.690 | 5.610 | 266.60 | | 2025.09.05 | 37.80 | 5.680 | 5.630 | ...

每经AI快讯，9月17日，威高股份(01066.HK)在港交所发布公告称，当日在香港斥资约1142.5万港元回 购股份195万股，每股回购价在5.82至5.9港元。 ...